| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. | Chief Financial Officer | Common Stock | 10,285 | $14,090 | $1.37 | 14 Apr 2025 | Direct |
| Inhibikase Therapeutics, Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 986,319 | 05 Jan 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| IKT | Inhibikase Therapeutics, Inc. | 05 Jan 2026 | 1 | $0 | 4 | Chief Financial Officer | 07 Jan 2026, 16:18 |
| IKT | Inhibikase Therapeutics, Inc. | 14 Apr 2025 | 1 | $0 | 4 | Chief Financial Officer | 16 Apr 2025, 16:06 |
| IKT | Inhibikase Therapeutics, Inc. | 14 Apr 2025 | 0 | $0 | 3 | Chief Financial Officer | 16 Apr 2025, 16:05 |